Melbourne, Apr 7, 2008 (ABN Newswire) - Doctors at Houston’s Texas Heart Institute held a press conference last Saturday (AEST) to provide an update on the ongoing multi-centre Phase 2 clinical trial of the proprietary mesenchymal precursor cell (MPC) technology in patients with heart attacks.
